[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498062":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":46,"responsibleParty":68,"collaborators":26,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":26,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":26,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LDL-C Lower-Target Group (25mg\u002FdL≤ LDL-C\u003C70mg\u002FdL)","EXPERIMENTAL","Participants randomized into the LDL-C lower-target arm will have a goal of 25mg\u002FdL≤ LDL-C\\\u003C70mg\u002FdL.\n\nPrescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level.",[13],"Procedure: Achieving a Target LDL-C level of 25mg\u002FdL≤ LDL-C\u003C70mg\u002FdL",{"label":15,"type":16,"description":17,"interventionNames":18},"LDL-C Higher-Target Group (70mg\u002FdL≤ LDL-C\u003C100mg\u002FdL)","ACTIVE_COMPARATOR","Participants randomized into the LDL-C lower-target arm will have a goal of 70mg\u002FdL≤ LDL-C\\\u003C100mg\u002FdL.\n\nPrescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level.",[19],"Procedure: Achieving a Target LDL-C level of 70mg\u002FdL≤ LDL-C\u003C100mg\u002FdL",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Achieving a Target LDL-C level of 25mg\u002FdL≤ LDL-C\u003C70mg\u002FdL","Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg\u002FdL≤ LDL-C\\\u003C70mg\u002FdL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.\n\nAt each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modifications, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Achieving a Target LDL-C level of 70mg\u002FdL≤ LDL-C\u003C100mg\u002FdL","Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg\u002FdL≤ LDL-C\\\u003C100mg\u002FdL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.\n\nAt each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modifications, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered.",[15],[32,36],{"name":33,"affiliation":34,"role":35},"Kefei Dou, MD, PhD","Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":34,"role":35},"Hao-Yu Wang, MD, PhD",[39,43],{"name":33,"role":40,"phone":41,"phoneExt":26,"email":42},"CONTACT","+86-10-13801032912","drdoukefei@126.com",{"name":37,"role":40,"phone":44,"phoneExt":26,"email":45},"+86-10-15810671272","wanghaoyu@fuwai.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","Beijing Municipality","100037","China","CN",{"type":56,"coordinates":57},"Point",[58,59],116.39723,39.9075,{"lat":59,"lon":58},[62,65],{"name":63,"role":40,"phone":64,"phoneExt":26,"email":42},"Kefei Dou, MD","+86-13801032912",{"name":66,"role":40,"phone":67,"phoneExt":26,"email":45},"Hao-Yu Wang, MD","+86-15810671272",{"type":69,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100498062","ldl-cholesterol-targets-in-older-patients-age75-years-with-ascvd-target-old-100498062",false,"NCT05765370","LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With Atherosclerotic Cardiovascular Disease (TARGET OLD)","Inclusion Criteria:\n\n1. Men or women ≥75 years of age\n2. Diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) with one or more of the following:\n\n   1. Diagnosis of coronary heart disease (one or more of the following criteria must be satisfied):\n\n      * Hospitalization for acute coronary syndrome\n      * Treatment or hospitalization for stable angina pectoris with documented ischemia on invasive or noninvasive testing\n      * History of myocardial infarction\n      * History of coronary revascularization procedure (eg, percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft surgery \\[CABG\\])\n      * Invasive diagnostic coronary angiography indicating \\>50% stenosis in at least one major epicardial coronary artery or CT-imaging (eg, CCTA\u002FMDCT) evidence of coronary atherosclerosis (\\>50% stenosis in at least two major epicardial coronary artery)\n   2. Diagnosis of atherosclerotic cerebrovascular or carotid disease (one or more of the following criteria must be satisfied):\n\n      * History of ischemic stroke or transient ischemic attack (TIA) confirmed by symptoms with a documented ischemic lesion on CT or MRI in the cerebral regions corresponding to the symptoms;\n      * Documented intracranial atherosclerotic stenosis on the basis of conventional cerebral angiography, magnetic resonance angiography, CT angiography, transcranial doppler ultrasound, and high-resolution MRI;\n      * Symptomatic carotid artery disease with ≥50% carotid arterial stenosis;\n      * Asymptomatic carotid artery disease with ≥70% carotid arterial stenosis per angiography or duplex ultrasound;\n      * History of carotid revascularization (catheter-based or surgical).\n   3. Diagnosis of atherosclerotic peripheral artery disease (one or more of the following criteria must be satisfied):\n\n      * History of aorto-iliac or peripheral arterial intervention (catheter-based or surgical).\n      * Prior non-traumatic amputation of a lower extremity due to peripheral artery disease\n      * History of intermittent claudication and one or more of the following:\n\n        1. An ankle\u002Farm blood pressure (BP) ratio \\\u003C 0.90, or\n        2. Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound\n3. Baseline LDL-C level should be satisfied:\n\n   * Patients were required to have a baseline LDL-C level ≥100mg\u002FdL (2.6mmol\u002FL) if they were taking a regimen of lipid-lowering therapy \\\u003C4 weeks or they had not previously received lipid-lowering therapy.\n   * Patients were required to have a baseline LDL-C level ≥70mg\u002FdL (1.8mmol\u002FL) if they were on stable treatment with lipid-lowering therapy ≥4 weeks\n4. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Subject was clinically unstable:\n\n   1. Hypotension, defined as sustained systolic blood pressure of \\\u003C90 mmHg due to cardiac failure with associated symptoms;\n   2. Unstable or severe pulmonary edema\u002Fdecompensated congestive heart failure;\n   3. Acute mitral regurgitation or acute ventricular septal defect;\n   4. Cardiogenic shock and\u002For need for mechanical\u002Fpharmacologic hemodynamic support\n   5. Ongoing Non-STEMI with biomarkers (cardiac troponin) still rising\n   6. Recent STEMI (≤7 days prior to randomization)\n   7. Recurrent symptoms of cardiac ischemia\n2. Moderate to severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification III or IV) or last known left ventricular ejection farction (LVEF) \\\u003C40%.\n3. Severe renal dysfunction, defined as creatinine clearance \\\u003C30 mL\u002Fmin or estimated glomerular filtration (eGFR) rate less than 30 ml\u002Fmin\u002F1.73 m2, or requirement for peritoneal dialysis or hemodialysis for renal insufficiency.\n4. History of hemorrhagic stroke or unknown classified stroke.\n5. Uncontrolled or recurrent ventricular tachycardia (such as ventricular fibrillation, recurrent and highly symptomatic ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications).\n6. Uncontrolled hypertension (greater than 180 mm Hg systolic and\u002For greater than 110 mm Hg diastolic at randomization visit).\n7. History or clinical evidence of active liver disease or hepatic dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN), or total bilirubin \\> 2 × ULN.\n8. Unexplained elevated creatine kinase (CK) concentration \\>5 × ULN or elevation due to known muscle disease.\n9. Planned or expected cardiac surgery, PCI or carotid stenting, or planned major noncardiac surgery during the study period. If angiography or revascularization is planned, patients may be screened and enrolled after all such planned procedures are completed.\n10. Active Malignancy (except nonmelanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) including those patients requiring surgery, chemotherapy, and\u002For radiation in the past 3 years.\n11. Drug or alcohol abuse, and inability\u002Funwillingness to abstain from drug abuse and excessive alcohol consumption during the study.\n12. Severe, concomitant noncardiovascular disease that is expected to reduce life expectancy to \\\u003C3 years\n13. Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies), or receiving other investigational agent(s)\n14. Subject has received drugs via a systemic route that have known major interactions with background statin therapy (eg, itraconazole, ketoconazole, and other antifungal azoles, erythromycin, clarithromycin, or cyclosporine nefazodone) within 1 month prior to randomization or is likely to require such treatment during the study period.\n15. Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal)\n16. Subject likely to not be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge.\n17. Any uncontrolled or serious disease, or any medical or surgical condition (such as known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction, or a chronic disease or infection \\[eg, HIV\\]), that may either interfere with participation in the clinical study and is not currently stable and appropriately managed in the judgment of the investigator, and\u002For put the subject at significant risk (according to investigator's judgment) if he\u002Fshe participates in the clinical study.\n18. Mental\u002Fpsychological impairment\u002Fneurocognitive disorder, or any other reason to expect patient difficulty in complying with the requirements of the study or understanding the goal and potential risks of participating in the study","ALL","75 Years",{"count":80,"type":81},4200,"ESTIMATED","INTERVENTIONAL",[84],"NA","To determine whether treating to an LDL-C target of 25 to \\\u003C70 mg\u002FdL is superior to an LDL-C target of 70 to \\\u003C100 mg\u002FdL with respect to major cardiovascular events (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) in patients aged ≥75 years with atherosclerotic cardiovascular disease (ASCVD).\n\nTo determine whether treating to an LDL-C target of 25 to \\\u003C70 mg\u002FdL is non-inferior to an LDL-C target of 70 to \\\u003C100 mg\u002FdL with respect to major safety events (hemorrhagic stroke, new-onset diabetes, muscle-related events, neurocognitive adverse events, new or recurrent cancer, cataract, or hepatic disorder \\[Alanine aminotransferase (ALT)\u002FAspartate aminotransferase (AST) \\>3× ULN, or total bilirubin \\>2× ULN\\]) in patients aged ≥75 years with ASCVD.",[87,88,89],"Atherosclerotic Cardiovascular Disease","Older Patients","LDL Cholesterol",[91,87,92,93,94,95,96],"LDL-C target","Older patients","Age≥75 years","Lipid-lowering therapy","Stain","PCSK9 inhibitor","2023-04-07",{"date":99,"type":100},"2023-04-10","ACTUAL",{"date":102,"type":100},"2023-03-24",{"date":104,"type":81},"2026-12-24",{"name":5,"class":6},1]